Last reviewed · How we verify

NCT05609279: JDRF-COE

Metabolic Phenotypes and Heterogeneity in Disease Burden Risk in Type 1 Diabetes

Completed Last updated 13 December 2024
What this trial tests

trial in Diabetes Mellitus in 60 participants. Completed in 30 August 2024.

Timeline
18 February 2021
Primary endpoint
30 August 2024
30 August 2024

Quick facts

Lead sponsorUniversity of Michigan
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date18 February 2021
Primary completion30 August 2024
Estimated completion30 August 2024
Sites1 location across United States

Conditions studied

Sponsor

University of Michigan

Who can join

Eligibility, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study focuses on individuals with type 1 diabetes (T1D) and seeks to comprehensively study and understand several aspects of T1D including: susceptibility to hypoglycemia (low blood sugar) and improvement in hypoglycemia risk using of advanced diabetes technologies, such as continuous glucose monitoring (CGM); the differences among individuals with T1D in the risk of chronic complications, and minimize the psychosocial impact of T1D.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing